Severe Acute Respiratory Syndrome

The suspected cause is infection with a coronavirus. Review material indicates that SARS-CoV and related pathogenic coronaviruses likely originated in bats, with spillover into humans. The grounding does not support a more specific aetiology beyond coronavirus infection and zoonotic emergence.

The grounding supports a coronavirus-driven respiratory disease process involving viral replication, immune responses, and immune evasion. Literature on related severe coronaviruses highlights receptor usage, including angiotensin-converting enzyme 2, and interactions with spike glycoprotein, viral envelope proteins, antibodies, and host cytokines. Pathology is described at a high level as atypical pneumonia with respiratory involvement, and the literature also covers innate immunity and genetic variation of the virus.

The supplied grounding does not identify specific host risk factors for severe acute respiratory syndrome. It does support transmission and zoonotic spillover as relevant epidemiologic features. Related review material indicates bat-borne coronaviruses as a source of emergence, but does not define individual susceptibility factors.

The grounding does not provide treatment guidance for severe acute respiratory syndrome itself. The only co-studied drug-class-level item is COVID-19 vaccines, which are preventive rather than treatment modalities. No standard therapeutic regimen or drug class for established SARS is supported by the supplied material.